Listing 13.14 Lung Cancer in 2026

Lung cancer is the leading cause of cancer death in the United States. The American Cancer Society projects 234,580 new lung cancer diagnoses in 2026 (116,310 in men, 118,270 in women) and 125,070 deaths, more than colorectal, breast, and prostate combined. Overall 5-year survival remains low at 25%, though outcomes vary enormously by stage and subtype: 65% for localized NSCLC dropping to 9% for distant metastatic, and just 7% for extensive-stage small-cell.

SSA Listing 13.14 recognizes three separate ways lung cancer meets the medical vocational disability rules. Small-cell lung cancer (SCLC) qualifies automatically at any stage. Non-small cell lung cancer (NSCLC) needs to be inoperable, unresectable, or recurrent. Superior sulcus (Pancoast) tumors get their own paragraph tied to multimodal therapy. This is the full walkthrough of each paragraph, the evidence you need, and how modern targeted therapy and immunotherapy shape residuals at the Continuing Disability Review.

The three paragraphs of Listing 13.14

Paragraph A: Non-small cell lung cancer inoperable, unresectable, or recurrent

Paragraph A covers non-small cell lung cancer that meets any of these three conditions:

• Inoperable: the patient cannot tolerate surgery due to comorbid conditions (poor pulmonary reserve, cardiac disease, poor performance status), OR the tumor location makes surgery impossible (e.g., extensive mediastinal invasion, involvement of great vessels, tracheal carina, or vertebral body beyond safe resection)
• Unresectable: the disease has spread beyond what surgery can remove with clear margins. Typically stage IIIB/IIIC (bulky N2, N3, or T4 with extensive local invasion) or stage IV (any distant metastases)
• Recurrent: the cancer has returned after initial curative-intent treatment, except for a local recurrence at the primary resection site that is being controlled by additional therapy

NSCLC covers about 85% of all lung cancer cases. The main subtypes are:

• Adenocarcinoma (40-50% of NSCLC) - most common, includes minimally invasive and invasive variants
• Squamous cell carcinoma (25-30%) - strongly linked to smoking, tends to arise centrally
• Large cell carcinoma (5-10%) - poorly differentiated, aggressive
• Adenosquamous, sarcomatoid, and other rare variants (5%)

The AJCC 8th edition stages that typically meet Paragraph A:

• Stage IIIA: T1-2 with N2 (ipsilateral mediastinal or subcarinal nodes), T3 with N1-N2, T4 with N0-N1. Often technically resectable but frequently treated with concurrent chemoradiation instead. Case-by-case whether surgery is offered.
• Stage IIIB: T1-2 with N3 (contralateral mediastinal, contralateral hilar, or supraclavicular nodes), T3-4 with N2. Almost always unresectable.
• Stage IIIC: T3-4 with N3. Always unresectable.
• Stage IV (any T, any N, M1): any distant metastasis. Includes ipsilateral pleural or pericardial effusion with malignant cells (M1a), separate tumor nodules in contralateral lung (M1a), single extrathoracic met (M1b), or multiple extrathoracic mets (M1c). All meet Paragraph A.

Common metastatic sites: brain (30-40% of stage IV NSCLC at some point), bone (30-40%), liver (20-25%), adrenal (15-20%), other lung (10-15%).

Paragraph B: Small-cell (oat cell) lung carcinoma

Paragraph B qualifies any confirmed small-cell (oat cell) lung carcinoma regardless of stage. SCLC accounts for about 13% of lung cancers and is universally aggressive: 5-year overall survival 7%, median survival 6-12 months for extensive-stage, 15-20 months for limited-stage with chemoradiation.

SCLC is classified as either:

• Limited-stage SCLC (LS-SCLC): disease confined to one hemithorax that can be safely encompassed in a single radiation field, including ipsilateral supraclavicular nodes. About 30-40% of SCLC at diagnosis. Standard treatment: concurrent platinum-etoposide chemotherapy + thoracic radiation, followed by prophylactic cranial irradiation if response achieved. 5-year survival 20-25%.
• Extensive-stage SCLC (ES-SCLC): any spread beyond a single radiation field, including distant metastases, contralateral thoracic disease, or malignant pleural effusion. About 60-70% at diagnosis. Standard treatment: platinum-etoposide + atezolizumab (Tecentriq) or durvalumab (Imfinzi) per IMpower133 and CASPIAN trials. 5-year survival <5%.

Diagnosis requires pathology with small-cell histology plus neuroendocrine markers (chromogranin A, synaptophysin, CD56, INSM1). Any confirmed SCLC meets 13.14B without staging requirements.

Paragraph C: Superior sulcus (Pancoast) tumor with multimodal therapy

Paragraph C qualifies superior sulcus (Pancoast) tumors treated with multimodal antineoplastic therapy (concurrent chemoradiation followed by surgical resection). Pancoast tumors are NSCLC arising at the lung apex, typically invading:

• Chest wall (ribs 1-3)
• Brachial plexus (C8, T1, T2 nerve roots) - causing arm pain and weakness
• Sympathetic chain and stellate ganglion - causing Horner syndrome (ptosis, miosis, anhidrosis)
• Subclavian vessels
• Vertebral body (T1-T3)

Modern treatment per Intergroup 0160 and SWOG S0220: concurrent cisplatin/etoposide + 45 Gy thoracic radiation, followed 3-5 weeks later by en-bloc surgical resection (lobectomy + chest wall resection + often T1 nerve root or vertebral body resection). This trimodality approach meets Paragraph C when initiated.

Diagnostic evidence required

SSA requires objective medical evidence for every 13.14 approval:

• Pathology report from tissue biopsy (transbronchial, CT-guided, endobronchial ultrasound EBUS, mediastinoscopy, or surgical resection) confirming lung cancer with histologic subtype and neuroendocrine markers if SCLC
• Molecular testing for NSCLC: EGFR mutations (exon 19 deletions, L858R, exon 20 insertions), ALK rearrangements (FISH or IHC), ROS1 rearrangements, BRAF V600E, KRAS mutations including G12C, MET exon 14 skipping, MET amplification, RET rearrangements, NTRK fusions, HER2 mutations. NCCN guidelines now require broad NGS testing for all metastatic non-squamous NSCLC.
• PD-L1 tumor proportion score (TPS) by IHC (22C3 or 28-8 antibody): <1%, 1-49%, or ≥50%. Determines eligibility for first-line immunotherapy monotherapy (pembrolizumab requires TPS ≥1%; single-agent preferred at TPS ≥50%).
• Staging workup: CT chest with contrast, PET-CT (FDG), brain MRI (routine for stage III+ and any SCLC), bone scan if indicated
• Pulmonary function tests (spirometry with FEV1 and DLCO) - matters for treatment planning and 3.02 residual analysis at CDR
• ECOG performance status - influences treatment eligibility

The Compassionate Allowance overlay

The CAL list includes four lung cancer categories in 2026:

• Small-cell lung cancer (any stage)
• Non-small cell lung cancer stage IIIB and IV
• Mesothelioma (separate listing 13.15 but often grouped)
• Pancoast tumor (superior sulcus)

CAL cases target 14-30 days for initial decision. Every DDS runs a CAL screen at intake. Lung cancer applications flagged as CAL move to expedited processing automatically.

Lung cancer with distant metastases also qualifies as a Terminal Illness (TERI) case when documented life expectancy is under 6 months.

Modern treatment residuals for the CDR

The 3-year rule under 13.00H1 applies (see our Section 13.00 walkthrough). At the 3-year CDR, SSA presumes medical improvement unless residuals sustain functional impairment. Lung cancer treatment produces significant residuals across multiple systems.

EGFR TKIs (osimertinib, erlotinib, afatinib, gefitinib, dacomitinib)

Osimertinib (Tagrisso) is first-line for EGFR-mutant NSCLC and adjuvant post-resection (per ADAURA and FLAURA trials). Common toxicities: rash (40-60%), diarrhea (40-50%), stomatitis (25%), interstitial lung disease (3-4% overall, 1-2% grade 3+, potentially fatal), QTc prolongation (5-10%), cardiac dysfunction with LVEF drop (5-10%). ILD from osimertinib qualifies under 3.02 chronic respiratory disorders when FEV1 or DLCO thresholds are met. Cardiotoxicity qualifies under 4.02 chronic heart failure at CDR.

ALK/ROS1 TKIs (alectinib, lorlatinib, brigatinib, entrectinib, crizotinib)

Alectinib (Alecensa) is first-line for ALK+ NSCLC (per ALEX trial). Lorlatinib (Lorbrena) is second-line or first-line in select cases. Common toxicities: fatigue (50-60%), edema (30-40%), myalgias (20-30%), cognitive effects with lorlatinib (30-40% mood/cognitive/speech), peripheral neuropathy, hypercholesterolemia and hypertriglyceridemia with lorlatinib requiring statin therapy in most patients. Lorlatinib CNS effects can qualify under 12.02 neurocognitive listings at CDR.

KRAS G12C inhibitors (sotorasib, adagrasib)

Sotorasib (Lumakras) and adagrasib (Krazati) for KRAS G12C-mutant NSCLC after prior therapy. Toxicities: diarrhea (30-50%), hepatotoxicity with LFT elevation (10-20% grade 3+), fatigue, nausea. Adagrasib adds QTc prolongation and renal dysfunction. Chronic hepatotoxicity requiring dose reductions can support ongoing disability.

Checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab, durvalumab, cemiplimab)

Used as first-line monotherapy, first-line with chemotherapy, or consolidation after chemoradiation (durvalumab per PACIFIC trial). Immune-related adverse events include:

• Pneumonitis (5-10% overall, 2-3% grade 3+) - qualifies under 3.02 with PFT decline
• Hypothyroidism (10-15% permanent) - qualifies under 9.00 endocrine
• Hyperthyroidism transitioning to hypothyroidism
• Adrenal insufficiency (2-5% permanent) - qualifies under 9.00
• Type 1 diabetes (<1% permanent) - qualifies under 9.08
• Colitis (2-4%) - severe cases qualify under 5.06 or 5.08
• Hepatitis (2-3% overall, 1-2% grade 3+)
• Nephritis (1-2%)
• Neurologic (myasthenia gravis, Guillain-Barre, encephalitis - rare but permanent)
• Cardiac (myocarditis - rare but often fatal)

Many irAEs are permanent even after immunotherapy stops. Endocrine irAEs (hypothyroidism, adrenal insufficiency, T1DM) are almost universally lifelong and often overlooked in CDR analysis.

Chemotherapy residuals

Platinum agents (cisplatin, carboplatin) cause chronic ototoxicity (hearing loss 20-40%, tinnitus), peripheral neuropathy (30-50% with cisplatin), nephrotoxicity (10-20% cisplatin). Pemetrexed causes fatigue, mucositis. Taxanes (paclitaxel, docetaxel) cause CIPN. Etoposide (for SCLC) contributes to myelosuppression and secondary MDS/AML risk (1-2% at 5+ years).

Radiation pneumonitis and fibrosis

Thoracic radiation causes acute pneumonitis in 10-20% (typically 1-6 months post-treatment) and chronic radiation fibrosis in 30-40% of long-term survivors. PFTs typically show restrictive pattern with reduced FVC and DLCO. Chronic radiation pneumonitis/fibrosis qualifies under 3.02 when FEV1 or DLCO drops below listing thresholds.

Post-surgical residuals

Lobectomy reduces FEV1 by 10-15% permanently. Pneumonectomy reduces FEV1 by 30-40% permanently. Chest wall resection (for Pancoast) causes chronic pain, decreased chest wall compliance, and often shoulder/upper extremity dysfunction. Brachial plexus dissection for Pancoast causes chronic upper extremity weakness and sensory loss - qualifies under 11.14 peripheral neuropathy at CDR.

Worked case examples

Case 1: Angela, 63, Pennsylvania, EGFR+ stage IV NSCLC on osimertinib

Angela presented with persistent cough and 15 lb weight loss over 3 months in January 2026. CT chest showed 4.5 cm right upper lobe mass with mediastinal adenopathy and multiple liver lesions. CT-guided biopsy of liver: metastatic adenocarcinoma with TTF-1+ CK7+ pattern typical of lung primary. NGS testing revealed EGFR exon 19 deletion. PD-L1 TPS 15%. Brain MRI showed 3 sub-cm asymptomatic brain metastases.

Clinical stage T2bN2M1c stage IV. SSDI application filed February 2026. CAL flag on stage IV NSCLC triggered expedited processing. Approval 21 days at Pennsylvania DDS. Onset backdated to first symptomatic date. Started osimertinib 80 mg daily plus stereotactic radiosurgery to brain lesions. Partial response at 3 months with resolution of 2/3 brain lesions and 70% shrinkage of primary + liver disease.

Case 2: Marcus, 58, Ohio, limited-stage SCLC

Marcus, a 40 pack-year smoker, presented with hemoptysis and a right hilar mass on CXR in March 2026. Bronchoscopy with EBUS-TBNA of hilar node showed small-cell carcinoma with strong chromogranin, synaptophysin, and INSM1 staining. Ki-67 90%. Staging PET-CT showed disease confined to right hemithorax with ipsilateral mediastinal and supraclavicular nodes. Brain MRI negative. Limited-stage SCLC.

Listing 13.14B met at diagnosis. CAL for SCLC triggered. SSDI application March 20, 2026. Approval 14 days at Ohio DDS. Started concurrent cisplatin/etoposide + 45 Gy BID thoracic radiation, followed by prophylactic cranial irradiation after response.

Case 3: David, 71, Florida, right superior sulcus Pancoast tumor

David presented with 6 months of progressive right shoulder pain radiating to the ulnar aspect of his right arm and hand, with new right eyelid droop and pupillary miosis (Horner syndrome). MRI chest showed 5 cm right upper lobe apex mass invading the first and second ribs and brachial plexus. Bronchoscopy showed squamous cell carcinoma. Staging PET-CT showed no distant disease. Clinical T4N0M0 stage IIIB superior sulcus tumor.

Listing 13.14C met on multimodal therapy plan (concurrent chemoradiation followed by planned surgical resection). CAL for Pancoast triggered. SSDI application March 2026. Approved 18 days at Florida DDS. Received concurrent cisplatin/etoposide + 45 Gy thoracic radiation, then en-bloc right upper lobectomy + chest wall resection (ribs 1-3) + T1 nerve root resection. Pathologic complete response on primary. Adjuvant durvalumab per PACIFIC trial extended to 12 months.

What to file with your application

1. Pathology report with histologic subtype (NSCLC vs SCLC vs specific subtype)
2. Molecular testing results (EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, NTRK, HER2, PD-L1) for NSCLC
3. Staging imaging: chest CT, PET-CT, brain MRI, bone scan if indicated
4. Pulmonary function tests (baseline)
5. Oncology consultation notes with stage and treatment plan
6. Any hospitalization records for treatment complications
7. Current medication list
8. ECOG performance status documentation

Related reading

Full section walkthrough: Section 13.00 cancer basics. Companion cancer listings: 13.05 lymphoma, 13.06 leukemia, 13.10 breast, 13.24 prostate. Companion piece: 13.18 colorectal cancer. Related: 3.11 lung transplantation.

Frequently asked questions

Next steps

If you were diagnosed with lung cancer, file for SSDI immediately after pathology and initial staging. Do not wait for treatment to start. The 5-month waiting period runs from your established onset date, so earlier filing means earlier back pay.